|22nd December 2020||Management Inc. Opaleye||496,277||Open or private purchase||$8.06||$3,999,992.62|
|22nd December 2020||Management Inc. Opaleye||657||Open or private purchase||$5.19||$3,412.98|
|22nd December 2020||Management Inc. Opaleye||15,900||Open or private purchase||$5.19||$82,597.32|
|21st December 2020||Management Inc. Opaleye||51,400||Open or private purchase||$5.24||$269,305.16|
|21st December 2020||Management Inc. Opaleye||2,059||Open or private purchase||$5.24||$10,787.92|
|18th December 2020||Management Inc. Opaleye||35,000||Open or private purchase||$5.31||$185,941.00|
|18th December 2020||Management Inc. Opaleye||1,400||Open or private purchase||$5.31||$7,437.64|
|2nd November 2020||Charles J Casamento||3,000||Open or private sale||$30.29||$90,863.70|
|21st October 2020||Management Inc. Opaleye||3,000||Open or private purchase||$4.40||$13,190.70|
|21st October 2020||Management Inc. Opaleye||5,656||Open or private purchase||$4.40||$24,868.87|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines.